Figure 3.

Rs34309 variant carrier status and presence of functional somatic mutations in the PI3K/PTEN/AKT/MTOR signaling pathway (green bars) and tumor lymphocyte infiltration (red bars) in the TCGA prostate cancer patient cohort. In UFG (rs34309-AA) carriers, 60% of tumor mutations (6/10) contained functional mutations, while only 27% of tumor mutations (27/99) had functional mutations in non-carriers (rs34309-AG+GG)(chi-square test, P = 0.03). Similarly, the proportion of tumors with lymphocyte infiltration was significantly higher in UFG-carriers (63.2%, 36/57) than non-carriers (46.2%, 168/364) (chi-square test, P = 0.017). Detailed distributions of mutations and lymphocyte infiltration were depicted in Table S4 and Table S5, respectively.